As of late 2025, the financial landscape continues to present a captivating duality: established giants navigate a complex global economy, while the fringes of the market buzz with the highly speculative, yet potentially explosive, world of penny stocks. For adventurous investors with a high-risk tolerance, these low-priced shares, typically trading
Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from Sept. 20 onward. Here's ETFs that may benefit.
The Biden administration announced support for the waiver of intellectual property protections for COVID-19 vaccines proposed by South Africa and India. Let’s take a look at ETFs that can suffer from the recent development:
